Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7440298 | 1.00 | EPHX1 (0.61) | EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3453982 | 0.98 | SMN1; SMN2 (0.61) | EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4303783 | 0.93 | — | — | |
| SCHEMBL224441 | 0.88 | — | — | |
| SCHEMBL10824411 | 0.84 | ALDH1A1 (0.60) | EPHX1SMN1; SMN2ALDH1A1NPSR1NPC1 | |
| SCHEMBL3075216 | 0.83 | EPHX1 (0.68) | EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9639138 | 0.83 | SMN1; SMN2 (0.67) | EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10587847 | 0.81 | ALDH1A1 (0.83) | EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL943151 | 0.80 | EPHX2 (0.58) | EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL854700 | 0.80 | MTNR1A (0.45) | EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115536673-B | Double-ion type cyclic onium salt probe for detecting high-efficiency haloxyfop-methyl and synthesis method thereof | 福建师范大学 | 2023-12-01 | — | — | CN | claimed |
| CN-115536673-A | Double-ion type cyclic onium salt probe for detecting high-efficiency haloxyfop-methyl and synthetic method thereof | 福建师范大学 | 2022-12-30 | — | — | CN | claimed |
| US-4494983-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1985-01-22 | — | — | US | claimed |
| EP-3340988-B1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI INC (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-26 | — | — | US | disclosed |
| EP-4192812-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-04 | — | — | EP | disclosed |
| CN-118126030-A | Preparation method of pyrazoline-1, 3, 4-oxadiazole thioacetamide derivative and application of pyrazoline-1, 3, 4-oxadiazole thioacetamide derivative as pesticide | 贵州大学 | 2024-06-04 | — | — | CN | disclosed |
| CN-117561240-A | Inhibitors of transglutaminase | 策迪拉有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| EP-0067382-A2 | N-cyclohexyl-chloroacetamides, their preparation and their use in combating undesired plant growth | BASF Aktiengesellschaft (DE) | 1982-12-22 | — | — | EP | disclosed |
| US-4310533-A | INHIBITING PLASMIN AND-OR TRYSIN ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-01-12 | — | — | US | disclosed |
| US-4278796-A | ANTIULCER AGENTS, ANTISECRETORY AGENTS, CYCLOHEXYLAMINOCARBONYLALKYL DERIVATIVES | CAMILLO CORVI S.P.A., VIALE DEI MILLE, 3 I-29 100 PIACENZA (ITALY) (IT) | 1981-07-14 | — | — | US | disclosed |
| US-4277479-A | ANTI-ASTHMATIC, HYPOTENSIVE, ANTI-ULCER, ANTIINFLAMMATORY, VASODILATION, ENZYME INHIBITORS, ANTICOAGULANTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-07-07 | — | — | US | disclosed |
| EP-0000023-B1 | OMEGA-SUBSTITUTED PENTYL UREAS, THEIR PREPARATION AND THEIR USE AS FUNGICIDES | BAYER AG (DE) | 1980-07-23 | — | — | EP | disclosed |
| US-4188401-A | Combating fungi with 1-(ω-substituted pentyl)-3-(2-cyano-acetyl)-ureas | BAYER AKTIENGESELLSCHAFT (DE) | 1980-02-12 | — | — | US | disclosed |
| EP-0000023-A1 | Omega-substituted pentyl ureas, their preparation and their use as fungicides | BAYER AG (DE) | 1978-12-20 | — | — | EP | disclosed |
| US-4123530-A | ANTIULCER AGENTS | CAMILLO CORVI S.P.A. (IT) | 1978-10-31 | — | — | US | disclosed |
| US-3972928-A | Regulating plant growth with quaternary phosphonium aliphatic carboxamide salts | BAYCHEM CORPORATION (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | EPHX1 718/4885HPGD 671/4885KMT2A 988/4885 |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | OGA, OGT, ENGASE | EPHX1 1099/4885HPGD 3738/4885KMT2A 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.